clinical trial · NCT05059444
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Guardant Health, Inc.·—·recruiting·n = 2,020
Bladder CarcinomaUreter CarcinomaRenal Pelvis CarcinomaNon-small Cell Lung CancerInvasive Breast CarcinomaCutaneous MelanomaEsophageal CarcinomaGastroesophageal Junction CarcinomaGuardant Reveal
brief summary
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
started
Sep 7, 2021
primary completion
Aug 1, 2029
completion
Aug 1, 2029
last updated
Aug 22, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol